Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - selenium as sodium selenate; clostridium chauvoei - toxoid; clostridium novyi type b - toxoid; clostridium perfringens type d toxoid; clostridium septicum - toxoid; clostridium tetani - toxoid; corynebacterium pseudotuberculosis - toxoid - misc. vaccines or anti sera - selenium as sodium selenate mineral-selenium active 0.5 g/l; clostridium chauvoei - toxoid vaccine-toxoid active 0.0 p; clostridium novyi type b - toxoid vaccine-toxoid active 0.0 p; clostridium perfringens type d toxoid vaccine-toxoid active 0.0 p; clostridium septicum - toxoid vaccine-toxoid active 0.0 p; clostridium tetani - toxoid vaccine-toxoid active 0.0 p; corynebacterium pseudotuberculosis - toxoid vaccine-toxoid active 0.0 p - immunotherapy - lamb | sheep | ewe | hogget | lamb | ovine | ram | weaner | wether - black disease | blackleg | cheesy gland | enterotoxaemia (pulpy kidney) | malignant oedema | selenium deficiency | tetanus | clostridium perfringens type d | lymphadenitis | lymphangitis | tetanus vaccination | white muscle disease

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

oz crop pty ltd - iprodione - suspension concentrate - iprodione carbamate active 500.0 g/l - fungicide

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - eszopiclone (unii: uzx80k71oe) (eszopiclone - unii:uzx80k71oe) - eszopiclone tablets are indicated for the treatment of insomnia. in controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance. the clinical trials performed in support of efficacy were up to 6 months in duration. the final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6 week study (adults only), at the end of both 2 week studies (elderly only) and at the end of the 6 month study (adults only). eszopiclone is contraindicated in patients with known hypersensitivity to eszopiclone. hypersensitivity reactions include anaphylaxis and angioedema [see warnings and precautions (5.3)] . there are no adequate and well-controlled studies in pregnant women. eszopiclone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral administration of eszopiclone to pregnant rats (62.5, 125, or 250 mg/kg/day) and rabbits (4, 8, or 16 mg/kg/day) thr